Alimera Sciences

Alimera Sciences, Inc., headquartered in Alpharetta, Georgia, is a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Alimera's European operations are conducted from London by its subsidiary, Alimera Sciences Limited. ILUVIEN (190 micrograms intravitreal implant in applicator) is a sustained release intravitreal implant used to treat patients with diabetic macular edema (DME). Each ILUVIEN implant delivers sustained sub-microgram levels of fluocinolone acetonide (FAc) for 36 months. ILUVIEN is injected in the back of the patient's eye with a 25-gauge needle, which allows for a self-sealing wound. In the two phase 3 clinical trials of ILUVIEN, collectively known as the FAME Study™, the most frequently reported adverse drug reactions included cataract development and increased ocular pressure. In the EU, ILUVIEN is approved for vision impairment associated with chronic DME considered insufficiently responsive to available therapies. ILUVIEN is approved in the U.S. for the treatment of DME in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP).
Company Growth (employees)
Alpharetta, US
Size (employees)
125 (est)
Alimera Sciences was founded in 2003 and is headquartered in Alpharetta, US

Key People at Alimera Sciences

Rick Eiswirth

Rick Eiswirth

Richard Eiswirth, Jr

Richard Eiswirth, Jr

Dave Holland

Dave Holland

senior VP of sales and marketing
Ken Greene

Ken Greene

Sr. Vice President & CSO
Susan Caballa

Susan Caballa

Sr. Vice President, Regulatory & Medical Affairs
Philip Ashman

Philip Ashman

Senior Vice President and European Managing Director

Alimera Sciences Office Locations

Alimera Sciences has offices in Alpharetta, Berlin, Lisbon, Hampshire
Alpharetta, US (HQ)
290 6120 Windward Pkwy
Hampshire, GB
Wellesley Rd
Berlin, DE
21 Cicerostraße

Alimera Sciences Metrics

Alimera Sciences Financial Metrics

Revenue (2016)

$34.3 m

Revenue growth (2015-16), %


Net income (2016)

($33.2 m)

Market capitalization (21-Mar-2017)

$93.1 m

Closing share price (21-Mar-2017)


Cash (31-Dec-2016)

$31 m
Alimera Sciences's current market capitalization is $93.1 m.
Alimera Sciences's revenue was reported to be $34.3 m in FY, 2016 which is a 53% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016


$1.9 m$8.4 m$22.4 m$34.3 m

Revenue growth, %


Cost of goods sold

$1.9 m

Gross profit

$9 k$7 m$20.7 m

Gross profit Margin, %


Operating expense total

$34.4 m$39.9 m$59.7 m


($46.2 m)($32.9 m)($39 m)($27.8 m)

EBIT margin, %


Net Income

($46.2 m)($35.9 m)($30.6 m)($33.2 m)
FY, 2013FY, 2014FY, 2015FY, 2016


$12.6 m$76.7 m$31.1 m$31 m

Accounts Receivable

$500 k$850 k$9.8 m$13.8 m


$3.5 m$3.2 m$2.7 m$2.1 m

Current Assets

$18.6 m$83.3 m$45.2 m$47.4 m

Total Assets

$19.6 m$109.4 m$70.5 m$70.2 m

Accounts Payable

$1.7 m$5 m$4 m$5 m

Current Liabilities

$4.9 m$10.5 m$39.9 m$9.1 m

Additional Paid-in Capital

$240.1 m$292.9 m$299.4 m$330.8 m

Retained Earnings

($277.3 m)($313.3 m)($343.9 m)($377.1 m)

Total Equity

$26.3 m$25.6 m

Financial Leverage

2.7 x2.7 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($46.2 m)($35.9 m)($30.6 m)($33.2 m)

Depreciation and Amortization

$138 k$659 k$2.6 m$2.8 m

Accounts Receivable

($483 k)($444 k)($8.9 m)($4.1 m)


($1.4 m)$206 k$405 k$556 k

Accounts Payable

($259 k)$3 m($487 k)$1.1 m

Cash From Operating Activities

($37.8 m)($24.3 m)($45.4 m)($25.1 m)

Purchases of PP&E

($973 k)($842 k)($451 k)($186 k)

Cash From Investing Activities

($973 k)($25.8 m)($451 k)($186 k)

Cash From Financing Activities

$1.7 m$114.7 m$625 k$25.4 m

Interest Paid

$607 k$1.2 m$4.2 m$4 m

Income Taxes Paid

$263 k$193 k

Alimera Sciences Market Value History

Alimera Sciences Online Presence

Alimera Sciences Company Life

You may also be interested in